Harbin Pharmaceutical Group Co Ltd (600664) - Total Assets
Based on the latest financial reports, Harbin Pharmaceutical Group Co Ltd (600664) holds total assets worth CN¥14.08 Billion CNY (≈ $2.06 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Harbin Pharmaceutical Group Co Ltd (600664) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Harbin Pharmaceutical Group Co Ltd - Total Assets Trend (1993–2024)
This chart illustrates how Harbin Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. See Harbin Pharmaceutical Group Co Ltd (600664) net assets for net asset value and shareholders' equity analysis.
Harbin Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Harbin Pharmaceutical Group Co Ltd's total assets of CN¥14.08 Billion consist of 75.1% current assets and 24.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 24.9% |
| Accounts Receivable | CN¥5.12 Billion | 35.0% |
| Inventory | CN¥1.89 Billion | 12.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥458.51 Million | 3.1% |
| Goodwill | CN¥39.16 Million | 0.3% |
Asset Composition Trend (1993–2024)
This chart illustrates how Harbin Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Harbin Pharmaceutical Group Co Ltd (600664) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Harbin Pharmaceutical Group Co Ltd's current assets represent 75.1% of total assets in 2024, an increase from 67.9% in 1993.
- Cash Position: Cash and equivalents constituted 24.9% of total assets in 2024, up from 2.3% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 35.0% of total assets.
Harbin Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Harbin Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.03 Billion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $36.83 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Humanwell Healthcare Group Co Ltd
SHG:600079
|
China | CN¥37.56 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Harbin Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.44 | 1.35 | 1.07 |
| Quick Ratio | 1.16 | 1.11 | 0.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.24 Billion | CN¥2.78 Billion | CN¥501.08 Million |
Harbin Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Harbin Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.57 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | CN¥14.62 Billion |
| Market Capitalization | $1.17 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Harbin Pharmaceutical Group Co Ltd's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Harbin Pharmaceutical Group Co Ltd's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Harbin Pharmaceutical Group Co Ltd (1993–2024)
The table below shows the annual total assets of Harbin Pharmaceutical Group Co Ltd from 1993 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥14.62 Billion ≈ $2.14 Billion |
+3.57% |
| 2023-12-31 | CN¥14.11 Billion ≈ $2.07 Billion |
+5.03% |
| 2022-12-31 | CN¥13.44 Billion ≈ $1.97 Billion |
+4.62% |
| 2021-12-31 | CN¥12.84 Billion ≈ $1.88 Billion |
+8.40% |
| 2020-12-31 | CN¥11.85 Billion ≈ $1.73 Billion |
-5.24% |
| 2019-12-31 | CN¥12.50 Billion ≈ $1.83 Billion |
+5.06% |
| 2018-12-31 | CN¥11.90 Billion ≈ $1.74 Billion |
-13.13% |
| 2017-12-31 | CN¥13.70 Billion ≈ $2.00 Billion |
-8.99% |
| 2016-12-31 | CN¥15.05 Billion ≈ $2.20 Billion |
+9.35% |
| 2015-12-31 | CN¥13.77 Billion ≈ $2.01 Billion |
-15.25% |
| 2014-12-31 | CN¥16.24 Billion ≈ $2.38 Billion |
-1.29% |
| 2013-12-31 | CN¥16.46 Billion ≈ $2.41 Billion |
+5.03% |
| 2012-12-31 | CN¥15.67 Billion ≈ $2.29 Billion |
+34.38% |
| 2011-12-31 | CN¥11.66 Billion ≈ $1.71 Billion |
-0.88% |
| 2010-12-31 | CN¥11.76 Billion ≈ $1.72 Billion |
+17.54% |
| 2009-12-31 | CN¥10.01 Billion ≈ $1.46 Billion |
+3.35% |
| 2008-12-31 | CN¥9.68 Billion ≈ $1.42 Billion |
+2.47% |
| 2007-12-31 | CN¥9.45 Billion ≈ $1.38 Billion |
+0.57% |
| 2006-12-31 | CN¥9.40 Billion ≈ $1.37 Billion |
+8.87% |
| 2005-12-31 | CN¥8.63 Billion ≈ $1.26 Billion |
+15.18% |
| 2004-12-31 | CN¥7.49 Billion ≈ $1.10 Billion |
+13.91% |
| 2003-12-31 | CN¥6.58 Billion ≈ $962.60 Million |
+10.49% |
| 2002-12-31 | CN¥5.95 Billion ≈ $871.18 Million |
+3.25% |
| 2001-12-31 | CN¥5.77 Billion ≈ $843.79 Million |
+29.60% |
| 2000-12-31 | CN¥4.45 Billion ≈ $651.09 Million |
+0.79% |
| 1999-12-31 | CN¥4.41 Billion ≈ $646.01 Million |
+22.11% |
| 1998-12-31 | CN¥3.62 Billion ≈ $529.05 Million |
+24.62% |
| 1997-12-31 | CN¥2.90 Billion ≈ $424.54 Million |
+16.60% |
| 1996-12-31 | CN¥2.49 Billion ≈ $364.10 Million |
+3.75% |
| 1995-12-31 | CN¥2.40 Billion ≈ $350.93 Million |
+2.15% |
| 1994-12-31 | CN¥2.35 Billion ≈ $343.55 Million |
+4.93% |
| 1993-12-31 | CN¥2.24 Billion ≈ $327.42 Million |
-- |
About Harbin Pharmaceutical Group Co Ltd
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cere… Read more